Combined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman, and Thailand

• Main Authors: B. M. Greenwood, A. J. Hall, M. G. Rowe, H. C. Whittle, M. George, A. A.K. Al-Ghassani, M. Elbualy, P. G. Malankar, A. J.M. Suleiman, G. B. Clements, E. T. Hay, C. Nairn, M. H. Riding, E. Bell, B. P. Hull, S. E. Robertson, P. F. Wright, H. Zoffmann, C. Aree, R. Samakoses, S. Simasathien, S. Migasena, P. Pitisuttitham, B. Ponrat, S. Tantivanich, S. Tharavanij, S. L. Cochi, R. W. Linkins, P. A. Patnarca, R. W. Sutter, L. Anderson, K. Maher, M. Pallansch, S. Penaranda
• Other Authors: Medical Research Council Laboratories Gambia
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/17711
• Institution: Mahidol University

To assess an immunization schedule combining oral (OPV) and inactivated poliovirus vaccines (IPV), we conducted a clinical trial in the Gambia, Oman, and Thailand. Children were randomized to receive one of the following schedules: OPV at birth, 6, 10, and 14 weeks of age; OPV at birth followed by both OPV and IPV at 6, 10, and 14 weeks of age; or placebo at birth followed by IPV at 6, 10, and 14 weeks of age. A total of 1685 infants were enrolled; 24-week serum specimens were available for 1291 infants (77%). Across the study sites at 24 weeks of age, the proportion of seropositive children in the combined schedule group was 95-99% for type 1, 99-100% for type 2, and 97-100% for type 3. In the Gambia and Oman, the combined schedule performed significantly better than OPV for type 1 (95-97% versus 88-90%) and type 3 (97-99% versus 72-73%). In the Gambia and Oman, seroprevalences in the IPV group were lower for type I (significantly lower in the Gambia); significantly lower for type 2; and significantly higher for type 3, compared with the OPV group. In Thailand, the IPV group had significantly lower proportions of children who were seropositive for each of the three types, compared with the OPV group. The responses to OPV in the Gambia, Oman, and Thailand were consistent with previous studies from these countries. IPV given at 6, 10, and 14 weeks of age provided inadequate serological protection against poliovirus, especially type 1. The combined schedule provided the highest levels of serum antibody response, with mucosal immunity equivalent to that produced by OPV alone.